Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04663035

Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

Recurrent Hepatocellular Carcinoma Clinical Trial

Official title:
CT-guided Thermal Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage Hepatocellular Carcinoma: a Randomized Controlled Phase II Clinical Trial

Clinical Trial Summary

This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular carcinoma.

Clinical Trial Description

Ablation is one of the main treatments for early recurrent HCC, and its immune stimulation is expected to improve the efficacy of anti-PD-1 immune checkpoint inhibitor therapy. Tislelizumab is a new immunotherapy agent with independent intellectual property rights in China, which is highly efficient and safe. It is of great value to combine Tislelizumab with ablation to reduce the risk of recurrence in HCC patients. In this study, early-stage HCC patients with high risk of recurrence would be included and randomly assigned to receive ablation plus Tislelizumab or ablation alone. The tumor recurrence, overall survival and safety would be observed and recorded to analyze whether Tislelizumab can reduce the recurrence rate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04663035
Study type Interventional
Source Sun Yat-sen University
Contact Ming Zhao, MD
Phone 86-20-87343272
Email zhaoming@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date December 21, 2020
Completion date December 18, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Completed NCT02728219 - Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion N/A
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2
Active, not recruiting NCT04677088 - TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Recruiting NCT03609268 - Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma N/A
Completed NCT02613156 - Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma N/A
Recruiting NCT02719782 - A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation Phase 1
Recruiting NCT04800497 - The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Active, not recruiting NCT03257761 - Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Phase 1
Terminated NCT02762266 - Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization Phase 3
Active, not recruiting NCT03655002 - IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Phase 1
Withdrawn NCT01318200 - Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) Phase 3
Completed NCT01015833 - Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 3
Withdrawn NCT05327738 - Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT04615143 - Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC Phase 2
Active, not recruiting NCT04805788 - Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer Phase 2
Withdrawn NCT03634683 - A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation Phase 1/Phase 2